cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Esperion Therapeutics Inc
14 own
17 watching
Current Price
$5.9
$-0.02
(-0.34%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
423.3M
52-Week High
52-Week High
8.87
52-Week Low
52-Week Low
3.28
Average Volume
Average Volume
2.17M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization423.3M
icon52-Week High8.87
icon52-Week Low3.28
iconAverage Volume2.17M
iconDividend Yield--
iconP/E Ratio--
What does the Esperion Therapeutics Inc do?
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Read More
How much money does Esperion Therapeutics Inc make?
News & Events about Esperion Therapeutics Inc.
Globe Newswire
25days ago
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year ...
Globe Newswire
27days ago
Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive milestone payments from partners upon regulatory approvals Fourth quarter 2022 U.S. net product revenue ...
Globe Newswire
1month ago
ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the Company plans to present at the J.P. Morgan 41st Annual Healthcare Conference as well as the LifeSci Partners 12th Annual Corporate Access Event. Both in-person events are taking place January 9-11th...
Globe Newswire
2 months ago
Demonstrates statistically significant and clinically meaningful results Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint Presentation of comprehensive data at a key medical conference in ...
Globe Newswire
2 months ago
Event to Include Expert-Led Discussions on State of Cardiovascular Disease Treatments and Remaining Unmet Needs Esperion Leadership Will Provide Overview of its Investigational Pipeline, Planned Scientific Focus, and Future Growth Drivers Virtual Program Begins at 10am ET Today, Wednesday, November ...
Frequently Asked Questions
Frequently Asked Questions
What is Esperion Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Esperion Therapeutics Inc shares?
plus_minus_icon
How can I buy Esperion Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Esperion Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Esperion Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Esperion Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Esperion Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Esperion Therapeutics Inc?
plus_minus_icon
What percentage is Esperion Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Esperion Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.9
$-0.02
(-0.34%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00